secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2026-09-25T21:15:39+00:00
Accession:  0001493152-26-044381
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Calidi Biotherapeutics hit with NYSE American notice; equity $3.1M vs $4.0M required
--------------------------------------------------------------------------------

- NYSE American notice dated Sept 21, 2026: stockholders' equity of $3.1M at June 30, 2026 is below the $4.0M minimum required by Company Guide Section 1003(a)(ii).
- Standard was triggered because Calidi reported net losses in three of its four most recent fiscal years ended December 31, 2025.
- Company must submit a compliance plan by Oct 21, 2026 and regain compliance by March 21, 2028; it is not eligible for any Section 1003(a) exemption, including the $50M market-cap exemption.
- CLDI keeps trading on NYSE American but gets a '.BC' below-compliance designation; delisting proceedings would begin if no plan is filed or the plan is rejected.
- Management says it is reviewing options and expects to submit the plan on or before the NYSE American deadline; the notice does not affect business operations or SEC reporting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226044381/0001493152-26-044381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226044381/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-044381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer